CUE · Cue Biopharma, Inc.

NasdaqHealthcareBiotechnology

Cue Biopharma Inc Is A Clinical-Stage Therapeutics Company Focused On Advancing A Robust Portfolio Of Potentially Transformative Therapies Aimed At Enabling Functional Cures Across Immunological Disorders. Its Product Pipeline Includes Cue-221, An Anti-Ige Antibody Candidate Being Developed For Allergic Diseases. The Company Has Also Developed The Immuno-Stat Platform For Targeting Disease-Related T Cells And Is Developing Cue-401, An Il-2 And Tgf-B Therapeutic Candidate For Autoimmune Diseases.

HealthcareNasdaqUSLow Float

$65.24

+43.2% latest move

Price & move as of the most recent catalyst (Sep 21) — not a live quote.

FLOAT

6.5M

FREE FLOAT %

90%

SHARES O/S

7.3M

MARKET CAP

$178.8M

EXCHANGE

Nasdaq

COUNTRY

CUE Catalyst History

Regulatory and ClinicalPositive Subgroup DataSep 21, 2026 · 4:05am ET

CUECue Biopharma, Inc.

Cue Biopharma Reports 60% Complete Hives Resolution for CUE-221 in Phase 2 Study

Post hoc analysis shows improvement over Omalizumab.

Be early on the next CUE spark.

Day Trader Sniper alerts you the instant a setup like this triggers.

How it works Download Free →